Rheumatology

March 20th 2025

Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, while price-linked discounts and prescribing quotas have shown mixed or uncertain results.

March 13th 2025

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 others that launched earlier this year.

March 12th 2025

Although more research is needed in pediatric patients, biosimilars could improve treatment access and reduce costs.

March 5th 2025

Adalimumab biosimilars differ from adalimumab in approved indications, concentration and dosage, and formulation.